US20030068389A1 - Antibacterial agent - Google Patents

Antibacterial agent Download PDF

Info

Publication number
US20030068389A1
US20030068389A1 US10/100,189 US10018902A US2003068389A1 US 20030068389 A1 US20030068389 A1 US 20030068389A1 US 10018902 A US10018902 A US 10018902A US 2003068389 A1 US2003068389 A1 US 2003068389A1
Authority
US
United States
Prior art keywords
bacteria
antibacterial agent
cold press
fraction
press oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/100,189
Other versions
US7098244B2 (en
Inventor
Tadahiro Hiramoto
Ryo Takeuchi
Minoru Hanada
Fumitaka Norose
Ritsuko Norose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takasago International Corp
Original Assignee
Takasago International Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takasago International Corp filed Critical Takasago International Corp
Assigned to TAKASAGO INTERNATIONAL CORPORATION reassignment TAKASAGO INTERNATIONAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HANADA, MINORU, HIRAMOTO, TADAHIRO, TAKEUCHI, RYO, NOROSE, RITSUKO
Publication of US20030068389A1 publication Critical patent/US20030068389A1/en
Priority to US10/812,170 priority Critical patent/US7060726B2/en
Application granted granted Critical
Publication of US7098244B2 publication Critical patent/US7098244B2/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/14Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
    • A01N43/16Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08Magnoliopsida [dicotyledons]
    • A01N65/36Rutaceae [Rue family], e.g. lime, orange, lemon, corktree or pricklyash
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/346Finished or semi-finished products in the form of powders, paste or liquids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/068Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G4/126Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/42Preservation of non-alcoholic beverages
    • A23L2/44Preservation of non-alcoholic beverages by adding preservatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463Organic compounds; Microorganisms; Enzymes
    • A23L3/3472Compounds of undetermined constitution obtained from animals or plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/04COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing vitamins, antibiotics, other medicaments
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/14COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing fruits, nuts, e.g. almonds, seeds, plants, plant extracts, essential oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair

Definitions

  • the present invention relates to an antibacterial agent containing coumarin analogues obtained from citrus cold press oil.
  • This antibacterial agent exhibits excellent antibacterial ability against various bacteria, also exerts a mild influence on humans and environment and does not change flavor and taste even after it is compounded, showing that it can be used for many purposes.
  • Synthetic antiseptics have been developed and used in various fields.
  • synthetic antiseptics such as Trichlosane and Parabene are known in food and drink fields and cosmetic fields.
  • These synthetic antiseptics have, to say in general, safety problems and are limited in the subjects to which these antiseptics are added and the amount to be added at present.
  • antibacterial agents of a natural origin.
  • these antibacterial agents not only are said to be by no means superior in antibacterial ability to the synthetic antiseptics but also involve such a problem that each affects the taste and flavor of the materials to which it is added.
  • acid-thermophilic bacteria genus Alicyclobacillus
  • pH acidic conditions
  • the present invention has the object of providing an antibacterial agent which is of a natural origin, exhibits excellent antibacterial ability, exerts a mild influence on humans and environment and has no influence on taste and flavor.
  • the inventors of the present invention have directed their attention to cold press oil which has been widely known and prepared from citrus fruits and have made earnest studies to prepare an antibacterial agent having more excellent antibacterial ability.
  • the inventors have found that the solvent-eluate fraction obtained by processing a high-boiling point portion of the citrus cold press oil using a silica gel column has high antibacterial ability. Based on this finding, further studies have been made to complete the present invention.
  • an antibacterial agent comprising a coumarin analogue obtained from a citrus fruit
  • an antibacterial agent for acid-thermophilic bacteria comprising a coumarin analogue obtained from a citrus fruit;
  • the antibacterial agent meant in the present invention is an agent comprising, as an essential component, a mixture of coumarin analogues obtained from the pericarp of citrus fruits.
  • the mixture of coumarin analogues may be obtained from the above pericarp by extraction with a solvent, it may also be obtained from citrus cold press oil derived from the pericarp of citrus fruits.
  • the mixture of coumarin analogues meant in the present invention is obtained from the pericarp of citrus fruits and a mixture containing plural compounds selected from compounds having a coumarin skeleton and compounds having a furocoumarin skeleton.
  • coumarin analogue mixtures There are many known coumarin analogue mixtures. Typical examples among these mixtures include auraptene, marmin, limettin, melanzin, 5-geranoxy-7-methoxycoumarin, citropten, bergapten, bergamottin, bergaptol, epoxybergamottin, dihydroxybergamottin and 5-geranoxy-psoralen.
  • these compounds are not intended to be limiting of the present invention.
  • the coumarin analogue is contained in the mixture in an amount of 40% by weight or more, more preferably 60% by weight or more and still more preferably 80% by weight or more in view of operability when it is added and compounded.
  • the citrus cold press oil meant in the present invention has been widely known.
  • the citrus cold press oil is usually prepared from citrus fruits, particularly, from the pericarp thereof.
  • the citrus cold press oil may be prepared from citrus fruits though a commercially available one may be used usually as the citrus cold press oil.
  • As the citrus fruit lemon, orange, lime, grapefruit, bergamot and the like are known. Among these fruits, lemon and lime are preferable in particular.
  • the above citrus cold press oil is separated into a high-boiling point fraction and a low-boiling point fraction by a usual method.
  • the citrus cold press oil is fractionated by a distillation method
  • the citrus cold press oil is introduced into a distiller and gradually heated under reduced pressure.
  • the distillate is called a low-boiling point fraction
  • the residue left in the distiller is called a high-boiling point fraction.
  • the high-boiling point fraction means the residue left after the citrus cold press oil is heated at 90 to 120° C. under reduced pressure (e.g., about 133 kPa).
  • This high-boiling point fraction is a mixture consisting of nonvolatile components.
  • this high-boiling point fraction is further fractionated.
  • the fractionating method various methods are known. As a typical method, a method of fractionating using a silica gel chromatographic method will be explained.
  • the above high-boiling point fraction may be pretreated in advance. For instance, it may be thickened by heating or made to have a low viscosity by adding a solvent. In this case, it is generally preferable to add the solvent in an amount of 0.1 to 30 parts by volume and preferably 0.5 to 20 parts by volume based on one part by weight of the extract.
  • the high-boiling point fraction is poured into, for example, a column for chromatography which is made and adjusted in advance, then an eluent constituted of a solvent is poured into the column to flow out the fraction retained temporally in the column with the solvent and the flown-out solvent is divided into several parts by a known means.
  • hydrocarbons such as n-pentane, n-hexane, branched hexane, benzene and toluene may be used as a non-polar solvent.
  • esters such as methyl acetate and ethyl acetate
  • ethers such as ethyl ether and alcohols such as methanol, ethanol and propanol
  • the solvent to be used in the present invention is not limited to these solvents.
  • each fraction it is preferable to flow out each fraction by using n-hexane, ethyl acetate or a mixed solvent of these solvents.
  • the mixed solvent there is no particular limitation on the proportion of each solvent.
  • the elution temperature the elution is carried out at ambient temperature. However, no particular limitation is imposed on the temperature and the elution may be carried out either at low temperatures or at high temperatures.
  • the fraction is first flown out only by hexane and then a mixed solvent of hexane and ethyl acetate is used, namely the content of hexane is decreased. Also, the fraction may be flown out only by ethyl acetate.
  • the solvent flown out by the above method using a known means is fractionated to obtain each fraction.
  • a fraction or a combination of plural fractions containing much coumarin analogues is processed to distill the solvents thereby obtaining a concentrate and thus an antibacterial agent can be prepared.
  • a little solvent may be left.
  • a treating step may be added in which the concentrate is treated repeatedly by refining operations such as high performance liquid chromatography. The crucial point is that the antibacterial agent is made to contain a significant coumarin analogue mixture.
  • the antibacterial agent thus obtained exhibits excellent antibacterial ability against various bacteria.
  • these bacteria may include dental caries causal bacteria, periodontosis bacteria, acid-thermophilic bacteria, acne bacteria, hircismus bacteria, dandruff bacteria, skin normal bacteria, abscess bacteria and food poisoning bacteria.
  • Acid-thermophilic bacteria Alicyclobacillus acidocaldarius, A. acidoterrestris, A. cycloheptanicus;
  • Lactic acid bacteria Sporolactobacillus inulinus ; Butyric acid bacteria: Clostridium pasteurianum, Clostridium butyricum;
  • the antibacterial agent thus obtained may be added directly to foods and the like. Also, it is possible to subject the antibacterial agent to use by dissolving or dispersing it in a proper liquid carrier or by mixing it with or adsorbing it onto a proper powder carrier. As the case may be, emulsifiers, dispersants, suspending agents, spreaders, penetrants, wetting agents or stabilizers may be added whereby the antibacterial agent is made into preparations such as emulsions, water-dispersible powders, powders or tablets.
  • the antibacterial agent is preferably used for foods, cosmetics and antibacterial preparations. Also, the antibacterial agent of the present invention may be used in combination with other known antibacterial agents or known compounds considered to have an antibacterial activity.
  • Examples of the above foods may include drinks such as a non-fruit juice drink, fruit juice-containing drink, lactic acid beverage and powdery drink, frozen sweets such as an ice cream, sherbet and ice sweet, deserts such as pudding, jelly, bavaroi and yoghurt, sweets such as a gum and candy and marine products made with boiled fish paste.
  • drinks such as a non-fruit juice drink, fruit juice-containing drink, lactic acid beverage and powdery drink
  • frozen sweets such as an ice cream, sherbet and ice sweet
  • deserts such as pudding, jelly, bavaroi and yoghurt
  • sweets such as a gum and candy and marine products made with boiled fish paste.
  • Examples of the fragrant products may include perfumes, toilet water, cologne and shower cologne.
  • Examples of the above fundamental cosmetics may include skin cream, cleansing cream, skin lotion, after-shave lotion, foundation, lipstick and talcum powder.
  • Examples of the above hair cosmetics may include shampoo agents such as a shampoo, rinse, conditioner, rinse-in-shampoo and treatment, hair dressing agents such as a pomade, hair tonic, hair liquid and hair jell, hair restorer, hair dying agent and cold wave agent.
  • shampoo agents such as a shampoo, rinse, conditioner, rinse-in-shampoo and treatment
  • hair dressing agents such as a pomade, hair tonic, hair liquid and hair jell, hair restorer, hair dying agent and cold wave agent.
  • Examples of the above toiletry products may include a toilet soap, bath soap and transparent soap.
  • bath agents may include a powdery bathing agent, solid bathing agent, solid foam bathing agent, bath oil and bubble bath.
  • Examples of the above detergents may include a powdery detergent for clothes, liquid detergent for clothes, softening and finishing agent, kitchen detergent, lavatory detergent, bath detergent, glass cleaner and mould-removing agent.
  • Examples of the above air care deodorants may include a gel-like air care deodorant, liquid air care deodorants, impregnated type air sol air care deodorant and mist type air care deodorant.
  • Examples of the above drugs may include a tablet, liquid drug, capsule type drug and granular drug.
  • the amount of the above antibacterial agent to be added to and compounded in a material is preferably 0.1 ⁇ g/ml to 50% by weight based on the material though it largely differs depending on the type of material and the type of bacterium.
  • the amount is less than 0.1 ⁇ g/ml, only insufficient antibacterial ability is obtained. Even if the antibacterial agent is added in an amount exceeding 50% by weight, this is economically disadvantageous though sufficient antibacterial ability is obtained.
  • the fraction was eluted with 30 L of n-hexane to obtain a fraction 1.
  • the fraction left in the column was eluted with a mixed solvent of ethyl acetate/hexane (volumetric ratio: 10:90), a mixed solvent of ethyl acetate/hexane (volumetric ratio: 20:80), a mixed solvent of ethyl acetate/hexane (volumetric ratio: 30:70), a mixed solvent of ethyl acetate/hexane (volumetric ratio: 50:50) and ethyl acetate 30 L each in volume to obtain a fraction 2, a fraction 3, a fraction 4, a fraction 5 and a fraction 6 respectively.
  • each fraction was placed in an evaporator to emit the solvents thereby obtaining dry solids.
  • the amount and coumarin analogue content of each fraction are shown in Table 1.
  • the content of the coumarin analogues is measured using a method in which 4 mg of the dry solid is dissolved in 50 ml of n-hexane or ethyl acetate and the solution was irradiated with ultraviolet light (wavelength: 311 nm) to measure the value of light absorption, from which the content is found.
  • the mixture of the dry solids obtained from each of the fractions 3, 4, 5 and 6 are called a coumarin analogue high concentration fraction and the mixture of the dry solids obtained from the fractions 1 and 2 are called a coumarin analogue low concentration fraction. Also, the mixtures of the dry solids obtained from the fractions 3 and 4 are called a concentrated fraction of the coumarin analogue high concentration fraction.
  • the above coumarin analogue high concentration fraction was dissolved in ethanol so as to adjust the solution to a concentration of 20% by weight to obtain a solution of the coumarin analogue high concentration fraction (CCF solution). Also, the concentrated fraction of the above coumarin analogue high concentration fraction was dissolved in ethanol so as to adjust the solution to a concentration of 20% by weight to obtain a solution of the concentrated fraction of the coumarin analogue high concentration fraction (CCMF solution)
  • Example 1 The same procedures as in Example 1 were carried out except that citrus cold press oil derived from a lime pericarp was used in place of the citrus cold press oil derived from a lemon pericarp, to obtain a coumarin analogue high concentration fraction, a concentrated fraction of the coumarin analogue high concentration fraction and a coumarin analogue low concentration fraction.
  • Example 2 Further, the same operation as in Example 1 was carried out to obtain a solution of the coumarin analogue high concentration fraction (CCF solution) and a solution of the concentrated fraction of the coumarin analogue high concentration fraction (CCMF solution).
  • CCF solution a solution of the coumarin analogue high concentration fraction
  • CCMF solution a solution of the concentrated fraction of the coumarin analogue high concentration fraction
  • S-1 Coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-2 Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-3 Coumarin analogue high concentration fraction derived from lime cold press oil
  • S-4 Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil
  • C-3 Coumarine analogue low concentration fraction derived from lemon cold press oil
  • C-4 Coumarine analogue low concentration fraction derived from lime cold press oil
  • the antibacterial agent of the present invention was observed to have a strong antibacterial activity equal to that of trichlosane.
  • the growth state of the medium in this Petri dish was compared with that in a Petri dish (blank) containing no sample and the concentration of the sample in which the growth of bacteria was not seen was defined as minimum growth inhibition concentration (MIC).
  • MIC minimum growth inhibition concentration
  • Test Bacteria Food poisoning bacteria
  • Staphylococcus aureus 209P IAM 12082 Staphylococcus aureus ATCC 6538 (Putrefying bacteria)
  • the serial twofold dilution solution of the sample is prepared in the same manner as in the agar medium dilution method. 30 ⁇ L of the sample solution having each concentration is added to 3 mL of a liquid medium (NYG medium), to which is further added 60 ⁇ L of a test bacteria solution and the medium is cultured at 30° C. for 48 hours.
  • a liquid medium NYG medium
  • a change of the turbidity of the medium is measured using a wavelength of 660 nm to find MIC.
  • the media 60 ⁇ L each are taken out from a test tube in which no growth of the bacteria is found and implanted in 3 mL of a new medium and cultured for 48 hours.
  • the minimum concentration at which no growth of the bacteria was observed is defined MBC.
  • S-1 Coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-2 Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-3 Coumarin analogue high concentration fraction derived from lime cold press oil
  • S-4 Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil
  • C-3 Coumarine analogue low concentration fraction derived from lemon cold press oil
  • C-4 Coumarine analogue low concentration fraction derived from lime cold press oil
  • Test Bacteria Food poisoning bacteria
  • Staphylococcus aureus 209P IAM 12082 Staphylococcus aureus ATCC 6538 (Putrefying bacteria)
  • the AAM liquid medium is cultured at 50° C. for 10 days.
  • AAM Aminyclobacillus Acidoterrestris Medium
  • liquid medium (Solution A) CaCl 2 .2H 2 O 0.25 g MgSO 4 .7H 2 O 0.50 g (NH 4 ) 2 SO 4 0.20 g Yeast extract 2.00 g Glucose 5.00 g KH 2 PO 4 3.00 g Water 1000.00 mL Adjusted to pH 4.0 using 1 M HCl solution (Solution B) Trace element solution SL-6 1.00 mL SL-6 ZnSO 4 .7H 2 O 0.10 g MnCl 2 .4H 2 O 0.03 g H 3 BO 3 0.30 g CoCl 2 .6H 2 O 0.20 g CuCl 2 .2H 2 O 0.01 g NiCl 2 .6H 2 O 0.02 g Na 2 MoO 4 .2H 2 O 0.03 g Water 1000.00 mL
  • S-1 Coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-2 Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil
  • Test Bacteria (genus Alicyclobacillus)
  • the samples were dissolved in ethanol to prepare a serial twofold dilution stage and 100 ⁇ L of each was added to 10 mL of a sterilized agar medium, which was then stirred sufficiently, then transferred to a 9-cm-diameter Petri dish and solidified at ambient temperature. 5 ⁇ L of a diluted test bacteria solution was implanted in the Petri dish and cultured at 37° C. for 72 hours. After the culturing was finished, the growth state of the medium in this Petri dish was compared with that in a Petri dish (blank) containing no sample and the concentration of the sample in which the growth of bacteria was not seen was defined as minimum growth inhibition concentration (MIC).
  • MIC minimum growth inhibition concentration
  • Sterilized Agar Medium (a) Propionibacterium acnes JCM 6473 (b) Propionibacterium acnes ATCC 6919 (c) Bacteriodes fragilis GAI 5560 Trypticase Soy Agar (BBL) in these cases (d) Corynebacterium xerosis JCM 1324 (e) Malassezia furfur IFO 0656 (f) Staphylococcus epidermides JCM 2414 (g) Corynebacterium minutissimum IFO 15361
  • S-1 Coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-2 Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil
  • S-3 Coumarin analogue high concentration fraction derived from lime cold press oil
  • S-4 Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil
  • C-3 Coumarine analogue low concentration fraction derived from lemon cold press oil
  • C-4 Coumarine analogue low concentration fraction derived from lime cold press oil
  • Example 14 Lemon tea Black tea leaves (Bx. 1.0) 200.0 g Granulated sugar 60.0 Lemon concentrated fruit juice 1.56 Vitamin C 0.1 CCMF solution 0.05 Purified water Proper amount 1000.0 g Sterilized at 80° C.
  • the antibacterial agent obtained in the present invention and comprising a mixture of coumarin analogues derived from citrus fruit has high antibacterial ability.
  • the antibacterial agent of the present invention exhibits the same high antibacterial ability as a synthetic bactericidal agent against various bacteria such as bacteria relative to oral care, e.g., dental caries bacteria and periodontosis bacteria, acid-thermophilic bacteria posing a problem in food industries, food poisoning bacteria and putrefying bacteria and acne bacteria, dandruff bacteria and skin normal bacteria posing a problem in cosmetic fields.
  • An influence on the flavor of foods of the antibacterial agent of the present invention is decreased and exerts a mild influence on humans and environment.
  • the antibacterial agent of the present invention is highly stable and therefore remarkably useful. This antibacterial agent can be widely used and, in particular, can be applied to cosmetics and foods and drinks.
  • putrefying bacteria cause, for instance, the putrefaction and deterioration of foods and therefore greatly damage the commercial value of the foods.
  • Food poisoning bacteria cause the putrefaction and deterioration of foods and at the same time, generate poisonous substances, which bring about seriously bad influence on those who eat such foods.
  • acid-thermophilic bacteria (genus Alicyclobacillus) grow in favor of high temperature (40 to 70° C.) and acidic (pH 2 to 6) conditions and acid-thermophilic mold (genus Byssochlamys) also grow in high temperature and acidic conditions as mentioned above. These bacteria have heat resistance and cannot be killed, for instance, under the usual bactericidal conditions (96 to 86° C., 2 minutes) of soft drinks.
  • the above acid-thermophilic bacteria can proliferate in highly acidic foods (e.g., canned drinks and acidic drinks containing fruits or fruit juice) having a pH less than 3.7, causing, for example, the occurrence of an unfavorable chemical odor, impaired taste and the occurrence of turbidity, indicating that these bacteria are a factor significantly damaging a product value.
  • highly acidic foods e.g., canned drinks and acidic drinks containing fruits or fruit juice
  • the use of the antibacterial agent of the present invention prevents the proliferation of thermostable acid-fast bacteria, thereby solving the aforementioned problem and can prevent the denaturation and putrefaction of foods and drinks without causing turbidity and precipitation.
  • the antibacterial agent since the antibacterial agent has the ability to inhibit the growth of dental caries bacteria, it can prevent the promotion of tooth decay and also the formation of dental plaque. Since the antibacterial agent of the present invention also has the ability to inhibit the growth of periodontosis bacteria, it not only prevents periodontosis but also inhibits the growth of bacteria which are a halitosis generating source and therefore an indirect deodorant effect can be expected. Also, because the growth of pathogenic bacteria in a pharynx zone and fungi is suppressed, it can be expected to help prevent catching colds.
  • the antibacterial agent of the present invention has the effect of suppressing the growth of hircismus bacteria, dandruff bacteria and abscess bacteria. Therefore, the effect of preventing body odor, anti-dandruff effect and anti-pimple effect are expected by including the antibacterial agent of the present invention in various cosmetics.
  • an unpleasant odor of washing which is generated when the washing is half-dried as experienced sometimes in the rainy season and the like is regarded to be largely caused by the growth of bacteria. This unpleasant odor is more reduced by including the present inventive product in a washing detergent.
  • the present inventive product can be used together with other antibacterial agents and materials having antibacterial activities. Moreover, the present invention ensures that the high-boiling portion of cold press oil, which portion is sometimes scrapped, can be utilized effectively.

Abstract

Provided is an antibacterial agent exhibiting an excellent antibacterial activity effect and exerting a mild influence on the environment and humans. The antibacterial agent of the present invention comprises, as an effective component, a mixture of coumarin analogues extracted from a citrus fruit pericarp, particularly a mixture of coumarin analogues obtained from citrus cold press oil.

Description

    BACKGROUND OF THE INVENTION
  • 1. Technical Field [0001]
  • The present invention relates to an antibacterial agent containing coumarin analogues obtained from citrus cold press oil. This antibacterial agent exhibits excellent antibacterial ability against various bacteria, also exerts a mild influence on humans and environment and does not change flavor and taste even after it is compounded, showing that it can be used for many purposes. [0002]
  • 2. Prior Art [0003]
  • Synthetic antiseptics have been developed and used in various fields. For example, synthetic antiseptics such as Trichlosane and Parabene are known in food and drink fields and cosmetic fields. These synthetic antiseptics have, to say in general, safety problems and are limited in the subjects to which these antiseptics are added and the amount to be added at present. [0004]
  • In the meantime, lysozyme, protamine, tea extracts, various spice extracts, various essential oils (components) and the like are known as antibacterial agents of a natural origin. However, these antibacterial agents not only are said to be by no means superior in antibacterial ability to the synthetic antiseptics but also involve such a problem that each affects the taste and flavor of the materials to which it is added. [0005]
  • Also, bacteria, for example, acid-thermophilic bacteria (genus Alicyclobacillus), which grow in favor of high temperature (40 to 70° C.) and acidic conditions (pH =2 to 6) are known. These bacteria cannot be perished in the usual bactericidal condition (86 to 96° C., 2 minutes) of soft drinks and proliferate while these drinks are stored, resulting in, for example, the occurrence of an unfavorable chemical odor, impaired taste and the occurrence of turbidity, indicating that these bacteria are a factor damaging a product value significantly. To avoid this problematic point, a method is proposed in which cane sugar fatty acid ester, which has been found to have an antibacterial effect, is added to low-acidity drinks such as coffee-flavored drinks. However, this ester has inferior dispersibility in an acidic range and is easily crystallized. From this reason, turbidity and precipitates are caused in the acidic drinks. Therefore, it is pointed out that this method has the disadvantage that the product value is impaired. [0006]
  • For this, there is a demand for an antibacterial agent which is of a natural origin, has superior antibacterial ability and has no influence on the taste and flavor of the product. [0007]
  • SUMMARY OF THE INVENTION
  • Accordingly, in order to solve the above problem, the present invention has the object of providing an antibacterial agent which is of a natural origin, exhibits excellent antibacterial ability, exerts a mild influence on humans and environment and has no influence on taste and flavor. [0008]
  • The inventors of the present invention have directed their attention to cold press oil which has been widely known and prepared from citrus fruits and have made earnest studies to prepare an antibacterial agent having more excellent antibacterial ability. As a result, the inventors have found that the solvent-eluate fraction obtained by processing a high-boiling point portion of the citrus cold press oil using a silica gel column has high antibacterial ability. Based on this finding, further studies have been made to complete the present invention. [0009]
  • According to the present invention, there is provided: [0010]
  • 1) an antibacterial agent comprising a coumarin analogue obtained from a citrus fruit; [0011]
  • 2) an antibacterial agent according to 1) wherein the coumarin analogue contains a coumarin analogue obtained from a citrus cold press oil derived from the pericarp of a citrus fruit; [0012]
  • 3) an antibacterial agent according to 1), wherein the coumarin analogue is obtained from a high-boiling point portion of a citrus cold press oil; [0013]
  • 4) an antibacterial agent according to 1), wherein the coumarin analogue is obtained from a fraction eluted by a solvent after a high-boiling point portion of the citrus cold press oil is carried on a support; [0014]
  • 5) an antibacterial agent for acid-thermophilic bacteria, the antibacterial agent comprising a coumarin analogue obtained from a citrus fruit; [0015]
  • 6) an oral care product comprising the aforementioned antibacterial agent; and [0016]
  • 7) a food comprising the aforementioned antibacterial agent. [0017]
  • PREFFERED EMBODIMENT OF THE INVENTION
  • The present invention will be hereinafter explained in detail. [0018]
  • The antibacterial agent meant in the present invention is an agent comprising, as an essential component, a mixture of coumarin analogues obtained from the pericarp of citrus fruits. Although the mixture of coumarin analogues may be obtained from the above pericarp by extraction with a solvent, it may also be obtained from citrus cold press oil derived from the pericarp of citrus fruits. [0019]
  • The mixture of coumarin analogues meant in the present invention is obtained from the pericarp of citrus fruits and a mixture containing plural compounds selected from compounds having a coumarin skeleton and compounds having a furocoumarin skeleton. There are many known coumarin analogue mixtures. Typical examples among these mixtures include auraptene, marmin, limettin, melanzin, 5-geranoxy-7-methoxycoumarin, citropten, bergapten, bergamottin, bergaptol, epoxybergamottin, dihydroxybergamottin and 5-geranoxy-psoralen. However, these compounds are not intended to be limiting of the present invention. [0020]
  • The higher the content of the above coumarin analogue in the mixture of compounds obtained from the pericarp of citrus fruit, the more greatly the antibacterial ability is improved and so a higher content of the coumarin is advantageous. In the antibacterial agent of the present invention, the coumarin analogue is contained in the mixture in an amount of 40% by weight or more, more preferably 60% by weight or more and still more preferably 80% by weight or more in view of operability when it is added and compounded. [0021]
  • The citrus cold press oil meant in the present invention has been widely known. The citrus cold press oil is usually prepared from citrus fruits, particularly, from the pericarp thereof. The citrus cold press oil may be prepared from citrus fruits though a commercially available one may be used usually as the citrus cold press oil. As the citrus fruit, lemon, orange, lime, grapefruit, bergamot and the like are known. Among these fruits, lemon and lime are preferable in particular. [0022]
  • Next, explanations will be furnished as to a method for obtaining a coumarin analogue from the citrus cold press oil. [0023]
  • The above citrus cold press oil is separated into a high-boiling point fraction and a low-boiling point fraction by a usual method. For example, when the citrus cold press oil is fractionated by a distillation method, the citrus cold press oil is introduced into a distiller and gradually heated under reduced pressure. Then, the distillate is called a low-boiling point fraction and the residue left in the distiller is called a high-boiling point fraction. In the present invention, the high-boiling point fraction means the residue left after the citrus cold press oil is heated at 90 to 120° C. under reduced pressure (e.g., about 133 kPa). This high-boiling point fraction is a mixture consisting of nonvolatile components. [0024]
  • Then, this high-boiling point fraction is further fractionated. As the fractionating method, various methods are known. As a typical method, a method of fractionating using a silica gel chromatographic method will be explained. [0025]
  • First, the above high-boiling point fraction may be pretreated in advance. For instance, it may be thickened by heating or made to have a low viscosity by adding a solvent. In this case, it is generally preferable to add the solvent in an amount of 0.1 to 30 parts by volume and preferably 0.5 to 20 parts by volume based on one part by weight of the extract. [0026]
  • Then, a method may be adopted in which the high-boiling point fraction is poured into, for example, a column for chromatography which is made and adjusted in advance, then an eluent constituted of a solvent is poured into the column to flow out the fraction retained temporally in the column with the solvent and the flown-out solvent is divided into several parts by a known means. In this invention, hydrocarbons such as n-pentane, n-hexane, branched hexane, benzene and toluene may be used as a non-polar solvent. Also, as a polar solvent, esters such as methyl acetate and ethyl acetate, ethers such as ethyl ether and alcohols such as methanol, ethanol and propanol can be used. However, the solvent to be used in the present invention is not limited to these solvents. [0027]
  • In the case of using usual silica gel chromatography, it is preferable to flow out each fraction by using n-hexane, ethyl acetate or a mixed solvent of these solvents. When the mixed solvent is used, there is no particular limitation on the proportion of each solvent. As to the elution temperature, the elution is carried out at ambient temperature. However, no particular limitation is imposed on the temperature and the elution may be carried out either at low temperatures or at high temperatures. [0028]
  • In the present invention, particularly the fraction is first flown out only by hexane and then a mixed solvent of hexane and ethyl acetate is used, namely the content of hexane is decreased. Also, the fraction may be flown out only by ethyl acetate. [0029]
  • Next, the solvent flown out by the above method using a known means is fractionated to obtain each fraction. A fraction or a combination of plural fractions containing much coumarin analogues is processed to distill the solvents thereby obtaining a concentrate and thus an antibacterial agent can be prepared. In this case, a little solvent may be left. Furthermore, a treating step may be added in which the concentrate is treated repeatedly by refining operations such as high performance liquid chromatography. The crucial point is that the antibacterial agent is made to contain a significant coumarin analogue mixture. [0030]
  • The antibacterial agent thus obtained exhibits excellent antibacterial ability against various bacteria. Examples of these bacteria may include dental caries causal bacteria, periodontosis bacteria, acid-thermophilic bacteria, acne bacteria, hircismus bacteria, dandruff bacteria, skin normal bacteria, abscess bacteria and food poisoning bacteria. [0031]
  • As specific examples of these bacteria, the following bacteria may be mentioned. [0032]
  • Dental caries causal bacteria; [0033] Streptococcus mutans, Actinomyces naeslundii, Actionmyces viscosus;
  • Periodontosis bacteria; [0034] Fusobacterium nuclestum, Prevotella intermedia, Porphyromonas gingivalis;
  • Calcification bacteria; [0035] Corynebacterium matruchotti;
  • Pathogenic bacteria in a pharynx zone; [0036] Streptococcus pyogenes, Haemophilus influenzae;
  • Acid-thermophilic bacteria; [0037] Alicyclobacillus acidocaldarius, A. acidoterrestris, A. cycloheptanicus;
  • Flatsour bacteria; [0038] Bacillus coagulans;
  • Lactic acid bacteria; [0039] Sporolactobacillus inulinus; Butyric acid bacteria: Clostridium pasteurianum, Clostridium butyricum;
  • Eumycetes; [0040] Byssochlamys uflva, Neosartorya fischeri;
  • Acne bacteria; [0041] Propionibacterium acnes;
  • Hircismus bacteria; [0042] Corynebacterium xerosis;
  • Dandruff bacteria; [0043] Malassezia furfur;
  • Skin normal bacteria; [0044] Staphylococcus aureus, Staphylococcus epidermides, Corynebacterium minutissimum;
  • Abscess bacteria; [0045] Bacteriodes fragilis;
  • Food poisoning bacteria; [0046] Vibrio parahaemolyticus, Campylobacter jejuni;
  • Putrefying bacteria: [0047] Bacillus subtilis; and etc.
  • The antibacterial agent thus obtained may be added directly to foods and the like. Also, it is possible to subject the antibacterial agent to use by dissolving or dispersing it in a proper liquid carrier or by mixing it with or adsorbing it onto a proper powder carrier. As the case may be, emulsifiers, dispersants, suspending agents, spreaders, penetrants, wetting agents or stabilizers may be added whereby the antibacterial agent is made into preparations such as emulsions, water-dispersible powders, powders or tablets. The antibacterial agent is preferably used for foods, cosmetics and antibacterial preparations. Also, the antibacterial agent of the present invention may be used in combination with other known antibacterial agents or known compounds considered to have an antibacterial activity. [0048]
  • As examples of the materials to which the antibacterial agent of the present invention may be added and compounded, foods, fragrant products, fundamental cosmetics, hair cosmetics, toiletry products, bath agents, body care products, detergent/finishing agents, flavorous deodorants and drugs are given, however the present invention is not limited to these materials. [0049]
  • Examples of the above foods may include drinks such as a non-fruit juice drink, fruit juice-containing drink, lactic acid beverage and powdery drink, frozen sweets such as an ice cream, sherbet and ice sweet, deserts such as pudding, jelly, bavaroi and yoghurt, sweets such as a gum and candy and marine products made with boiled fish paste. [0050]
  • Examples of the fragrant products may include perfumes, toilet water, cologne and shower cologne. [0051]
  • Examples of the above fundamental cosmetics may include skin cream, cleansing cream, skin lotion, after-shave lotion, foundation, lipstick and talcum powder. [0052]
  • Examples of the above hair cosmetics may include shampoo agents such as a shampoo, rinse, conditioner, rinse-in-shampoo and treatment, hair dressing agents such as a pomade, hair tonic, hair liquid and hair jell, hair restorer, hair dying agent and cold wave agent. [0053]
  • Examples of the above toiletry products may include a toilet soap, bath soap and transparent soap. [0054]
  • Examples of the above bath agents may include a powdery bathing agent, solid bathing agent, solid foam bathing agent, bath oil and bubble bath. [0055]
  • Examples of the above detergents may include a powdery detergent for clothes, liquid detergent for clothes, softening and finishing agent, kitchen detergent, lavatory detergent, bath detergent, glass cleaner and mould-removing agent. [0056]
  • Examples of the above air care deodorants may include a gel-like air care deodorant, liquid air care deodorants, impregnated type air sol air care deodorant and mist type air care deodorant. [0057]
  • Examples of the above drugs may include a tablet, liquid drug, capsule type drug and granular drug. [0058]
  • Generally, the amount of the above antibacterial agent to be added to and compounded in a material is preferably 0.1 μg/ml to 50% by weight based on the material though it largely differs depending on the type of material and the type of bacterium. When the amount is less than 0.1 μg/ml, only insufficient antibacterial ability is obtained. Even if the antibacterial agent is added in an amount exceeding 50% by weight, this is economically disadvantageous though sufficient antibacterial ability is obtained.[0059]
  • EXAMPLES
  • The present invention will be explained in more detail by way of examples and comparative examples, which, however, are not intended to be limiting of the present invention. [0060]
  • Example 1
  • Preparation of an Antibacterial Agent Derived from a Lemon Pericarp [0061]
  • 1 kg of citrus cold press oil derived from a lemon pericarp was placed in a heating container disposed in a distiller and gradually heated under reduced pressure. Volatile compounds were vaporized, liquefied in a cooler and accumulated in a receiving section. When the temperature of the citrus cold press oil in the heating container reached 120° C. under pressure, the heating was stopped. The amount of the residue (high-boiling point fraction) left in the heating container was 67 g. [0062]
  • A very small amount of ethyl acetate was added to 200 g of this high-boiling point fraction, which was then poured into a silica gel chromatographic column filled with 4 kg of silica gel and the high-boiling point fraction was carried on the silica gel. [0063]
  • Then, the fraction was eluted with 30 L of n-hexane to obtain a fraction 1. In succession, the fraction left in the column was eluted with a mixed solvent of ethyl acetate/hexane (volumetric ratio: 10:90), a mixed solvent of ethyl acetate/hexane (volumetric ratio: 20:80), a mixed solvent of ethyl acetate/hexane (volumetric ratio: 30:70), a mixed solvent of ethyl acetate/hexane (volumetric ratio: 50:50) and ethyl acetate 30 L each in volume to obtain a fraction 2, a fraction 3, a fraction 4, a fraction 5 and a fraction 6 respectively. [0064]
  • Each fraction was placed in an evaporator to emit the solvents thereby obtaining dry solids. The amount and coumarin analogue content of each fraction are shown in Table 1. Here, the content of the coumarin analogues is measured using a method in which 4 mg of the dry solid is dissolved in 50 ml of n-hexane or ethyl acetate and the solution was irradiated with ultraviolet light (wavelength: 311 nm) to measure the value of light absorption, from which the content is found. [0065]
    TABLE 1
    Yield and coumarin analogue content of each fraction
    Fraction # Lemon Lime
    1 30 (0)* 23 (1)
    2 34 (18) 22 (31)
    3 20 (87) 15 (100)
    4 6 (99) 17 (100)
    5 5 (99) 19 (91)
    6 5 (63) 4 (89)
  • The mixture of the dry solids obtained from each of the fractions 3, 4, 5 and 6 are called a coumarin analogue high concentration fraction and the mixture of the dry solids obtained from the fractions 1 and 2 are called a coumarin analogue low concentration fraction. Also, the mixtures of the dry solids obtained from the fractions 3 and 4 are called a concentrated fraction of the coumarin analogue high concentration fraction. [0066]
  • The above coumarin analogue high concentration fraction was dissolved in ethanol so as to adjust the solution to a concentration of 20% by weight to obtain a solution of the coumarin analogue high concentration fraction (CCF solution). Also, the concentrated fraction of the above coumarin analogue high concentration fraction was dissolved in ethanol so as to adjust the solution to a concentration of 20% by weight to obtain a solution of the concentrated fraction of the coumarin analogue high concentration fraction (CCMF solution) [0067]
  • Example 2
  • Preparation of an Antibacterial Agent Derived from a Lime Pericarp [0068]
  • The same procedures as in Example 1 were carried out except that citrus cold press oil derived from a lime pericarp was used in place of the citrus cold press oil derived from a lemon pericarp, to obtain a coumarin analogue high concentration fraction, a concentrated fraction of the coumarin analogue high concentration fraction and a coumarin analogue low concentration fraction. [0069]
  • Further, the same operation as in Example 1 was carried out to obtain a solution of the coumarin analogue high concentration fraction (CCF solution) and a solution of the concentrated fraction of the coumarin analogue high concentration fraction (CCMF solution). [0070]
  • Test Example 1
  • Test for Antibacterial Ability (Measurement of Minimum Growth Inhibition Concentration (MIC) using an Agar Medium Dilution Method) [0071]
  • The samples shown below were dissolved in ethanol to prepare a serial twofold dilution stage and 100 μL of each was added to 10 mL of a sterilized agar medium (Trypticase Soy Agar (BBL)), which was then stirred sufficiently, then transferred to a 9-cm-diameter Petri dish and solidified at ambient temperature. 5 μL of a diluted test bacteria (shown below) solution was implanted in the Petri dish and cultured at 37° C. for 72 hours. After the culturing was finished, the growth state of the medium in this Petri dish was compared with that in a Petri dish (blank) containing no sample and the concentration of the sample in which the growth of bacteria was not seen was defined as MIC. The results obtained are shown in Table 2. [0072]
  • Sample [0073]
  • S-1: Coumarin analogue high concentration fraction derived from lemon cold press oil [0074]
  • S-2: Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil [0075]
  • S-3: Coumarin analogue high concentration fraction derived from lime cold press oil [0076]
  • S-4: Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil [0077]
  • Control plot [0078]
  • C-1: Trichlosane [0079]
  • C-2: Butylparabene [0080]
  • C-3: Coumarine analogue low concentration fraction derived from lemon cold press oil [0081]
  • C-4: Coumarine analogue low concentration fraction derived from lime cold press oil [0082]
  • Test Bacteria [0083]
  • (Dental Caries Causal Bacteria) [0084]
  • (a) [0085] Streptococcus mutans JCM 5175
  • (b) [0086] Actinomyces naeslundii JCM 8350
  • (c) [0087] Actionmyces viscosus JCM 8352
  • (Periodontosis Bacteria) [0088]
  • (d) [0089] Fusobacterium nuclestum JCM 6328
  • (e) [0090] Prevotella intermedia JCM 6322
  • (f) [0091] Porphyromonas gingivalis JCM 8525
    TABLE 2
    Qualification of activity (MIC: ppm)
    Bacterium C-1 C-2 C-3 C-4 S-1 S-2 S-3 S-4
    (a) Streptococcus mutans 6.3 200 >1000 >1000 100 100 100 100
    (b) Actinomyces naeslundii 3.1 100 >1000 >1000 12.5 12.5 12.5 12.5
    (c) Actionmyces viscosus 3.1 100 >1000 >1000 12.5 12.5 6.3 3.1
    (d) Fusobacterium nuclestum 3.1 100 >1000 >1000 12.5 6.3 6.3 3.1
    (f) Porphyromonas gingivalis 3.1 50 >1000 >1000 6.3 6.3 3.1 1.6
    (e) Prevotella intermedia 3.1 100 >1000 >1000 12.5 25.0 3.1 12.5
  • The antibacterial agent of the present invention was observed to have a strong antibacterial activity equal to that of trichlosane. [0092]
  • Test Example 2
  • Test for Antibacterial Ability (Measurement of Minimum Growth Inhibition Concentration (MIC) using an Agar Medium Dilution Method) [0093]
  • Qualification Test Method 1: [0094]
  • Measurement of minimum growth inhibition concentration (MIC) using an agar medium dilution method The samples shown below were dissolved in ethanol to prepare a serial twofold dilution stage and 100 μL of each was added to 10 mL of a sterilized agar medium (Mueller Hinton medium (Difco)), which was then stirred sufficiently, then transferred to a 9-cm-diameter Petri dish and solidified at ambient temperature. 5 μL of a diluted test bacteria solution was implanted in the Petri dish and cultured at 37° C. for 72 hours. After the culturing was finished, the growth state of the medium in this Petri dish was compared with that in a Petri dish (blank) containing no sample and the concentration of the sample in which the growth of bacteria was not seen was defined as minimum growth inhibition concentration (MIC). [0095]
  • The results obtained are shown in Table 3. [0096]
  • Test Bacteria [0097]
    (Food poisoning bacteria)
    Staphylococcus aureus 209P IAM 12082
    Staphylococcus aureus ATCC 6538
    (Putrefying bacteria)
    Bacillus subtilis PCI 219 IFO 3134
  • Qualification Method 2: [0098]
  • Measurements of MIC and Minimum Bactericidal Concentration (MBC) by using a Liquid Medium Dilution Method [0099]
  • The serial twofold dilution solution of the sample is prepared in the same manner as in the agar medium dilution method. 30 μL of the sample solution having each concentration is added to 3 mL of a liquid medium (NYG medium), to which is further added 60 μL of a test bacteria solution and the medium is cultured at 30° C. for 48 hours. [0100]
  • A change of the turbidity of the medium is measured using a wavelength of 660 nm to find MIC. The media 60 μL each are taken out from a test tube in which no growth of the bacteria is found and implanted in 3 mL of a new medium and cultured for 48 hours. The minimum concentration at which no growth of the bacteria was observed is defined MBC. [0101]
  • The results are shown in Table 4. [0102]
  • Sample [0103]
  • S-1: Coumarin analogue high concentration fraction derived from lemon cold press oil [0104]
  • S-2: Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil [0105]
  • S-3: Coumarin analogue high concentration fraction derived from lime cold press oil [0106]
  • S-4: Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil [0107]
  • Control Plot [0108]
  • C-1: Trichlosane [0109]
  • C-2: Butylparabene [0110]
  • C-3: Coumarine analogue low concentration fraction derived from lemon cold press oil [0111]
  • C-4: Coumarine analogue low concentration fraction derived from lime cold press oil [0112]
  • Test Bacteria [0113]
    (Food poisoning bacteria)
    Staphylococcus aureus 209P IAM 12082
    Staphylococcus aureus ATCC 6538
    (Putrefying bacteria)
    Bacillus subtilis PCI 219 IFO 3134
  • [0114]
    TABLE 3
    Qualification of activity using a
    qualification test method 1 (MIC: ppm):
    Bacterium C-2 C-3 C-4 S-2 S-4
    Bacillus 200 >1000 >1000 25 6.3
    subtilis
    PCI 219
    Staphylococcus 100 >1000 >1000 12.5 6.3
    aureus 209P
    Staphylococcus 200 >1000 >1000 25 6.3
    aureus ATCC
  • The samples S-2 and S-4 used in an amount in the order of ppm were observed to have more effective antibacterial activity against the above test bacteria. [0115]
    TABLE 4
    Qualification of activity using a
    qualification test method 2 (MIC, MBC: ppm)
    BACTERIUM C-1 S-1 S-3
    MIC
    Staphylococcus 0.244 3.91 1.95
    aureus IAM12082
    Staphylococcus 0.977 3.91 3.91
    aureus
    ATCC 6538
    MBC
    Staphylococcus 0.977 62.5 15.6
    aureus IAM12082
    Staphylococcus 1.95 500.0 250.0
    aureus
    ATCC6538
  • From the results of the measurement of MBC, trichlosane has strong bactericidal activity, whereas the samples S-1 and S-3 are bacteriostatic and therefore the antibacterial effect of these samples may be concluded to be due to the bacteriostatic action. Therefore, the samples S-1 and S-3 may be concluded to exert a mild influence on humans and the environment. [0116]
  • Test Example 3
  • Test for Antibacterial Ability [0117]
  • Test Method [0118]
  • 1) 0.5 mL of a standard strain solution stored in sterilized-purified water is diluted with 5 mL of sterilized phosphoric acid buffer physiological salt solution. After the diluted strain solution is heated at 80° C. for 10 minutes, it is added to each AAM liquid medium having a volume of 5 mL in an amount of 100 μL (the number of spores in 100 μL=about 1,000,000). [0119]
  • 2) The sample is added to the AAM liquid medium implanted with the standard bacteria such that it is contained in each concentration. [0120]
  • 3) The AAM liquid medium is cultured at 50° C. for 10 days. [0121]
  • 4) Whether the bacteria which go into operation are present or not is observed using a microscope (the bacteria is globular when they form a spore and are in a dormant stage but the bacteria which go into operation become bacilli, so that both can be easily discriminated from each other by using a microscope). [0122]
  • The results obtained by the observation using a microscope are shown in Table 5. The case where any bacterium which germinates are not present at all is evaluated as (−) and the case where the presence of a bacterium which germinates is confirmed is evaluated as (+) [0123]
  • AAM (Alicyclobacillus Acidoterrestris Medium) liquid medium: [0124]
    (Solution A)
    CaCl2.2H2O 0.25 g
    MgSO4.7H2O 0.50 g
    (NH4) 2SO4 0.20 g
    Yeast extract 2.00 g
    Glucose 5.00 g
    KH2PO4 3.00 g
    Water 1000.00 mL
    Adjusted to pH 4.0 using 1 M
    HCl solution
    (Solution B)
    Trace element solution SL-6 1.00 mL
    SL-6
    ZnSO4.7H2O 0.10 g
    MnCl2.4H2O 0.03 g
    H3BO3 0.30 g
    CoCl2.6H2O 0.20 g
    CuCl2.2H2O 0.01 g
    NiCl2.6H2O 0.02 g
    Na2MoO4.2H2O 0.03 g
    Water 1000.00 mL
  • The solution A and the solution B are mixed to obtain an AAM liquid medium. [0125]
  • Sample [0126]
  • S-1: Coumarin analogue high concentration fraction derived from lemon cold press oil [0127]
  • S-2: Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil [0128]
  • S-3: Coumarin analogue high concentration fraction derived from lime cold press oil [0129]
  • S-4: Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil [0130]
  • Test Bacteria (genus Alicyclobacillus) [0131]
  • [0132] Alicyclobacillus acidocaldarius
  • [0133] A. acidoterrestris
  • [0134] A. cycloheptanicus
  • (Flatsour Bacteria) [0135]
  • [0136] Bacillus coagulans
    TABLE 5
    Amount A. A.
    added Alicyclobacillus acido cyclo Bacillus
    (ppm) acidocaldarius terrestris heptanicus coagulans
    S-1 5 ± ± ±
    50
    S-2 0.5 ± ± ± ±
    5
    50
    S-3 5 ± ± ±
    50
    S-4 0.5 ± ± ± ±
    5
    50
  • Explanations of the Symbols in the Table [0137]
  • “−” indicates the case where no bacterium which germinates are present. [0138]
  • “±” indicates the case where bacteria which germinate are observed though the number of such bacteria is very small (several bacteria). [0139]
  • Test Example 4
  • Test for Antibacterial Ability (Measurement of Minimum Growth Inhibition Concentration (MIC) using an Agar Medium Dilution Method) [0140]
  • The samples were dissolved in ethanol to prepare a serial twofold dilution stage and 100 μL of each was added to 10 mL of a sterilized agar medium, which was then stirred sufficiently, then transferred to a 9-cm-diameter Petri dish and solidified at ambient temperature. 5 μL of a diluted test bacteria solution was implanted in the Petri dish and cultured at 37° C. for 72 hours. After the culturing was finished, the growth state of the medium in this Petri dish was compared with that in a Petri dish (blank) containing no sample and the concentration of the sample in which the growth of bacteria was not seen was defined as minimum growth inhibition concentration (MIC). [0141]
  • The results obtained are shown in Table 6. [0142]
  • Sterilized Agar Medium: [0143]
    (a) Propionibacterium acnes JCM 6473
    (b) Propionibacterium acnes ATCC 6919
    (c) Bacteriodes fragilis GAI 5560
    Trypticase Soy Agar (BBL) in these cases
    (d) Corynebacterium xerosis JCM 1324
    (e) Malassezia furfur IFO 0656
    (f) Staphylococcus epidermides JCM 2414
    (g) Corynebacterium minutissimum IFO 15361 
  • Mueller Hinton Medium (Difco) in these Cases [0144]
  • Sample [0145]
  • S-1: Coumarin analogue high concentration fraction derived from lemon cold press oil [0146]
  • S-2: Concentrated fraction of a coumarin analogue high concentration fraction derived from lemon cold press oil [0147]
  • S-3: Coumarin analogue high concentration fraction derived from lime cold press oil [0148]
  • S-4: Concentrated fraction of a coumarin analogue high concentration fraction derived from lime cold press oil [0149]
  • Control Plot [0150]
  • C-2: Butylparabene [0151]
  • C-3: Coumarine analogue low concentration fraction derived from lemon cold press oil [0152]
  • C-4: Coumarine analogue low concentration fraction derived from lime cold press oil [0153]
  • Test Bacteria [0154]
  • (Acne Bacteria) [0155]
    Propionibacterium acnes JCM 6473
    Propionibacterium acnes ATCC 6919
    (Hircismus bacteria)
    Corynebacterium xerosis JCM 1324
    (Dandruff bacteria)
    Malassezia furfur IFO 0656
    (Skin normal bacteria)
    Staphylococcus epidermides JCM 2414
    Corynebacterium minutissimum IFO 15361 
    (Abscess bacteria)
    Bacteriodes fragilis GAI 5560
  • [0156]
    TABLE 6
    Minimum growth inhibition concentration (MIC): ppm
    Bacterium C-2 C-3 C-4 S-1 S-2 S-3 S-4
    (f) Staphylococcus epidermides 200 50 25 12.5 12.5
    (g) Corynebacterium minutissimum 200 25 12.5 6.3 3.1
    (d) Corynebacterium xerosis 50 25 12.5 12.5 6.3
    (e) Malassezia furfur 100 12.5 12.5 6.3 6.3
    Bacillus subtilis 200 25 25 12.5 6.3
    PCI 219
    (a) Propionibacterium 100 >1000 >1000 12.5 12.5 6.3 6.3
    acnes JCM 6473
    (b) Propionibacterium 100 >1000 >1000 12.5 12.5 6.3 3.1
    acnes ATCC 6919
    (c) Bacteriodes fragilis 50 25 25 3.1 3.1
  • In the table, “−” indicates that no experiment was made. [0157]
    (Example 3) Toothpaste
    Dicalcium phosphate 10.0% by weight
    Sodium laurylsulfate 2.0
    Sodium carboxymethyl cellulose 0.5
    Sodium saccharide 0.02
    Peppermint flavor 1.0
    CCF solution 5.0
    Glycerol Proper amount
    100.0% by weight
    (Example 4) Mouth detergent
    Ethyl alcohol 10.0% by weight
    Polyoxyethylene hydrogenated castor oil 2.0
    Peppermint flavor 0.5
    Sodium saccharide 0.02
    Glycerol 10.0
    FD & Color
    CCF solution 0.25
    Purified water Proper amount
    100.0% by weight
    (Example 5) Candy
    Sugar powder 50.0% by weight
    Starch syrup 33.0
    Citric acid 1.0
    CCF solution 0.25
    Purified water Proper amount
    100.0% by weight
    (Example 6) Chewing gum
    Gum base 21.0% by weight
    Sugar powder 63.9
    Corn starch 12.5
    Lemon type flavor 1.0
    Acidifying agent 0.6
    CCF solution 0.25
    100.0% by weight
    (Example 7) Lozenge
    Starch 98.45% by weight
    Peppermint type powder flavor 0.8
    Sucrose fatty acid ester 0.5
    CCMF solution 0.25
    100.0% by weight
    (Example 8) De-bacterial agent
    Ethanol 20.0% by weight
    CCMF solution 5.0
    Purified water Proper amount
    100.0% by weight
    (Example 9) Fruit juice drink
    Orangeade (Brix: 10.8, acidity: 0.38) 107.0 g
    Fructose, glucose, liquid sugar
    Citric acid 1.0
    Sodium citrate 0.3
    Orange concentrated fruit juice 51.8
    Water-soluble orange flavor 1.0
    CCF solution 0.1
    Water Proper amount
    1000 g
    (Example 10) Sport drink
    Sugar 31.0 g
    Glucose 15.7
    Citric acid 1.0
    Calcium lactate 0.679
    Sodium citrate 0.3
    Sodium chloride 0.28
    Potassium chloride 0.22
    Vitamin C 0.864
    Sodium L-glutamate 0.03
    Niacin 0.013
    Calcium pantothenate 0.007
    Vitamin B6 0.0022
    Vitamin B12 0.000006
    Lemon flavor 1.0
    CCMF solution 0.1
    Purified water Proper amount
    1000 g
    (Example 11) Coffee-flavored drink
    Regular coffee 50.0 g
    Granulated sugar 50.0
    Milk 150.0
    Emulsifier (fatty acid ester) 0.5
    Coffee flavor 1.0
    Milk flavor 0.8
    CCMF solution 0.1
    Purified water Proper amount
    1000.0 g
    (Example 12) Carbonated drink
    Fructose, glucose, liquid sugar 127.0 g
    Citric acid 1.24
    Purified water 200.0
    Lemon flavor 0.12
    CCMF solution 0.05
    Carbonated water Proper amount
    1000.0 g
    (Example 13) Fruit juice jelly
    Apple juice 6.0 g
    Starch syrup 3.5
    Granulated sugar 13.0
    Malic acid 0.21
    Gelling agent 0.9
    Sodium citrate 0.05
    Caramel dye 0.08
    Apple flavor 0.2
    CCMF solution 0.01
    Purified water Proper amount
    100.0 g
    Sterilized at 80° C. for 20 minutes
    (Example 14) Lemon tea
    Black tea leaves (Bx. 1.0) 200.0 g
    Granulated sugar 60.0
    Lemon concentrated fruit juice 1.56
    Vitamin C 0.1
    CCMF solution 0.05
    Purified water Proper amount
    1000.0 g
    Sterilized at 80° C. for 10 minutes
    (Example 15) Powder detergent
    C-12-C-18 Palay sodium sulfate 15.0 g
    Sodium carbonate 15.0
    Sodium methasilicate 13.0
    Sodium citrate 15.0
    Carboxymethyl cellulose 2.0
    Sodium sulfate 38.0
    Musk tree type flavor 1.0
    CCF solution 1.0
    100.0 g
    (Example 16) Shampoo
    Sodium Laureth Sulfate 40.0 g
    Sodium Cocoamphoacetate 10.0
    Cocamide DEA 2.0
    Butylene Glycol 2.0
    Citric Acid 0.35
    Sodium Chloride 0.1
    Paraben 0.3
    Tetrasodium EDTA 0.1
    Flavor 0.5
    CCF solution 1.0
    Purified water Proper amount
    100.0 g
    (Example 17) Emollient cream
    Cetyl alcohol 5.0 g
    Stearic acid 3.0
    Vaseline 5.0
    Squalane 10.0
    Glycerol tri2-ethylhexanate 7.0
    Dipropylene glycol 5.0
    Glycerol 5.0
    Propylene glycol monostearate 3.0
    POE (20) cetyl alcohol ether 3.0
    Triethanolamine 1.0
    Parabene 0.3
    Perfume 1.0
    CCF solution 1.0
    Purified water Proper amount
    100.0 g
    (Example 18) Antiperspirant
    PEG-7 glyceryl cocoate 2.0 g
    Hydrogenated oil 5.0
    Myristyl Myristate 15.0
    Cyclometicone 35.0
    Stearyl alcohol 20.0
    Stearyl Isononenoate 3.0
    Al-chlorohydrate 20.0
    Perfume 0.5
    CCF solution 1.0
    100.0 g
  • The antibacterial agent obtained in the present invention and comprising a mixture of coumarin analogues derived from citrus fruit has high antibacterial ability. Specifically, the antibacterial agent of the present invention exhibits the same high antibacterial ability as a synthetic bactericidal agent against various bacteria such as bacteria relative to oral care, e.g., dental caries bacteria and periodontosis bacteria, acid-thermophilic bacteria posing a problem in food industries, food poisoning bacteria and putrefying bacteria and acne bacteria, dandruff bacteria and skin normal bacteria posing a problem in cosmetic fields. An influence on the flavor of foods of the antibacterial agent of the present invention is decreased and exerts a mild influence on humans and environment. In addition, the antibacterial agent of the present invention is highly stable and therefore remarkably useful. This antibacterial agent can be widely used and, in particular, can be applied to cosmetics and foods and drinks. [0158]
  • Among the above bacteria, putrefying bacteria cause, for instance, the putrefaction and deterioration of foods and therefore greatly damage the commercial value of the foods. Food poisoning bacteria cause the putrefaction and deterioration of foods and at the same time, generate poisonous substances, which bring about seriously bad influence on those who eat such foods. [0159]
  • Therefore, by adding the antibacterial agent of the present invention to foods, the effect of improving the stability of foods stored for a long time and the effect of preventing food poisoning are attained. [0160]
  • Also, acid-thermophilic bacteria (genus Alicyclobacillus) grow in favor of high temperature (40 to 70° C.) and acidic (pH 2 to 6) conditions and acid-thermophilic mold (genus Byssochlamys) also grow in high temperature and acidic conditions as mentioned above. These bacteria have heat resistance and cannot be killed, for instance, under the usual bactericidal conditions (96 to 86° C., 2 minutes) of soft drinks. Accordingly, the above acid-thermophilic bacteria can proliferate in highly acidic foods (e.g., canned drinks and acidic drinks containing fruits or fruit juice) having a pH less than 3.7, causing, for example, the occurrence of an unfavorable chemical odor, impaired taste and the occurrence of turbidity, indicating that these bacteria are a factor significantly damaging a product value. [0161]
  • The use of the antibacterial agent of the present invention prevents the proliferation of thermostable acid-fast bacteria, thereby solving the aforementioned problem and can prevent the denaturation and putrefaction of foods and drinks without causing turbidity and precipitation. [0162]
  • Moreover, since the antibacterial agent has the ability to inhibit the growth of dental caries bacteria, it can prevent the promotion of tooth decay and also the formation of dental plaque. Since the antibacterial agent of the present invention also has the ability to inhibit the growth of periodontosis bacteria, it not only prevents periodontosis but also inhibits the growth of bacteria which are a halitosis generating source and therefore an indirect deodorant effect can be expected. Also, because the growth of pathogenic bacteria in a pharynx zone and fungi is suppressed, it can be expected to help prevent catching colds. [0163]
  • Moreover, the antibacterial agent of the present invention has the effect of suppressing the growth of hircismus bacteria, dandruff bacteria and abscess bacteria. Therefore, the effect of preventing body odor, anti-dandruff effect and anti-pimple effect are expected by including the antibacterial agent of the present invention in various cosmetics. [0164]
  • Also, an unpleasant odor of washing which is generated when the washing is half-dried as experienced sometimes in the rainy season and the like is regarded to be largely caused by the growth of bacteria. This unpleasant odor is more reduced by including the present inventive product in a washing detergent. [0165]
  • The present inventive product can be used together with other antibacterial agents and materials having antibacterial activities. Moreover, the present invention ensures that the high-boiling portion of cold press oil, which portion is sometimes scrapped, can be utilized effectively. [0166]

Claims (26)

What is claimed is:
1. An antibacterial agent comprising a coumarin analogue extracted from a pericarp of a citrus fruit.
2. An antibacterial agent according to claim 1, wherein the coumarin analogue is extracted from a citrus cold press oil derived from the pericarp of a citrus fruit.
3. An antibacterial agent according to claim 1, wherein the coumarin analogue is extracted from the high-boiling point portion of a citrus cold press oil.
4. An antibacterial agent according to claim 1, wherein the coumarin analogue is extracted from a fraction eluted by a solvent after the high-boiling point portion of the citrus cold press oil is carried on a support.
5. An antibacterial agent for thermostable acid-fast bacteria, the antibacterial agent comprising a coumarin analogue extracted from the pericarp of a citrus fruit.
6. An oral care product comprising the antibacterial agent as claimed in claim 1.
7. An oral care product comprising the antibacterial agent as claimed in claim 2.
8. An oral care product comprising the antibacterial agent as claimed in claim 3.
9. An oral care product comprising the antibacterial agent as claimed in claim 4.
10. A food comprising the antibacterial agent as claimed in claim 1.
11. A food comprising the antibacterial agent as claimed in claim 2.
12. A food comprising the antibacterial agent as claimed in claim 3.
13. A food comprising the antibacterial agent as claimed in claim 4.
14. A method of inhibiting the growth of bacteria comprising contacting the bacteria with an antibacterial agent comprising a coumarin analogue extracted from a pericarp of a citrus fruit.
15. The method according to claim 14, wherein the coumarin analogue is extracted from a citrus cold press oil derived from the pericarp of a citrus fruit.
16. The method according to claim 14, wherein the coumarin analogue is extracted from the high-boiling point portion of a citrus cold press oil.
17. The method according to claim 14, wherein the coumarin analogue is extracted from a fraction eluted by a solvent after the high-boiling point portion of the citrus cold press oil is carried on a support.
18. A method of inhibiting the growth of bacteria comprising contacting the bacteria with an antibacterial agent for thermostable acid-fast bacteria, the antibacterial agent comprising a coumarin analogue extracted from the pericarp of a citrus fruit.
19. The method according to claim 14, wherein said bacteria are present in an oral care product.
20. The method according to claim 15, wherein said bacteria are present in an oral care product.
21. The method according to claim 16, wherein said bacteria are present in an oral care product.
22. The method according to claim 17, wherein said bacteria are present in an oral care product.
23. The method according to claim 14, wherein said bacteria are present in a food product.
24. The method according to claim 15, wherein said bacteria are present in a food product.
25. The method according to claim 16, wherein said bacteria are present in a food product.
26. The method according to claim 17, wherein said bacteria are present in a food product.
US10/100,189 2001-03-19 2002-03-19 Antibacterial agent Expired - Lifetime US7098244B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/812,170 US7060726B2 (en) 2001-03-19 2004-03-30 Antibacterial agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001079489A JP4424871B2 (en) 2001-03-19 2001-03-19 Antibacterial agent
JP2001-79489 2001-03-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/812,170 Division US7060726B2 (en) 2001-03-19 2004-03-30 Antibacterial agent

Publications (2)

Publication Number Publication Date
US20030068389A1 true US20030068389A1 (en) 2003-04-10
US7098244B2 US7098244B2 (en) 2006-08-29

Family

ID=18935930

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/100,189 Expired - Lifetime US7098244B2 (en) 2001-03-19 2002-03-19 Antibacterial agent
US10/812,170 Expired - Lifetime US7060726B2 (en) 2001-03-19 2004-03-30 Antibacterial agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/812,170 Expired - Lifetime US7060726B2 (en) 2001-03-19 2004-03-30 Antibacterial agent

Country Status (2)

Country Link
US (2) US7098244B2 (en)
JP (1) JP4424871B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090204187A1 (en) * 2008-02-12 2009-08-13 Mankovitz Roy J Soil-based compositions and methods for removal of toxins from mammals
JPWO2016148149A1 (en) * 2015-03-16 2018-01-18 サントリーホールディングス株式会社 Liquid composition comprising citrus peel essential oil
US10232047B2 (en) 2011-12-20 2019-03-19 Vyome Biosciences Private Limited Topical oil composition for the treatment of fungal infections

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4660088B2 (en) * 2003-12-12 2011-03-30 ライオン株式会社 Deodorant and deodorant composition, cosmetic composition and cleaning composition containing the deodorant
JP4606099B2 (en) * 2004-09-09 2011-01-05 高砂香料工業株式会社 New compounds
JP5393367B2 (en) * 2009-09-14 2014-01-22 サントリー食品インターナショナル株式会社 Taste imparting agent
CN107007480B (en) * 2015-11-30 2021-08-17 富士胶片株式会社 Gel-like oil-in-water emulsion composition, external skin preparation, and method for producing oil-in-water emulsion composition
SG11201807558VA (en) 2016-03-04 2018-10-30 Nobuto WASHIO Beverage product and method and apparatus for producing beverage product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925660A (en) * 1985-11-21 1990-05-15 Mitsui Petrochemical Industries, Ltd. Curable compositions for dental drugs having sustained release property
US5457030A (en) * 1990-12-28 1995-10-10 Microscan, Inc. Method and composition for determining antimicrobial susceptibility of the majority clinically significant Gram postitive organism
US5985912A (en) * 1996-12-20 1999-11-16 Pfizer Inc. 4-hydroxy coumarin derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE623572A (en) 1961-10-13
GB1110848A (en) 1965-06-18 1968-04-24 Stauffer Chemical Co Control of growth of fungi and bacteria
US3454548A (en) 1967-03-20 1969-07-08 Bristol Myers Co Noviosyloxy coumarin containing compounds
JPH0816048B2 (en) * 1988-05-17 1996-02-21 株式会社ロッテ Oral composition
CA2069146A1 (en) 1991-05-24 1992-11-25 Frank Dininno 2-benzocoumarinyl carbapenems
US5624951A (en) 1992-09-01 1997-04-29 Pfizer Inc. 4-hydroxy coumarin derivatives with antibacterial activity
JP2996838B2 (en) 1993-07-12 2000-01-11 株式会社ポッカコーポレーション Antibacterial agent
JP3571111B2 (en) * 1995-05-23 2004-09-29 株式会社ポッカコーポレーション Antimicrobial agent
JPH09255547A (en) 1996-03-22 1997-09-30 Kao Corp Skin preparation for external use
JPH10175814A (en) * 1996-12-16 1998-06-30 Ichimaru Pharcos Co Ltd Skin preparation for external use and bathing agent containing garcinia extract

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925660A (en) * 1985-11-21 1990-05-15 Mitsui Petrochemical Industries, Ltd. Curable compositions for dental drugs having sustained release property
US5457030A (en) * 1990-12-28 1995-10-10 Microscan, Inc. Method and composition for determining antimicrobial susceptibility of the majority clinically significant Gram postitive organism
US5985912A (en) * 1996-12-20 1999-11-16 Pfizer Inc. 4-hydroxy coumarin derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090204187A1 (en) * 2008-02-12 2009-08-13 Mankovitz Roy J Soil-based compositions and methods for removal of toxins from mammals
US10232047B2 (en) 2011-12-20 2019-03-19 Vyome Biosciences Private Limited Topical oil composition for the treatment of fungal infections
JPWO2016148149A1 (en) * 2015-03-16 2018-01-18 サントリーホールディングス株式会社 Liquid composition comprising citrus peel essential oil

Also Published As

Publication number Publication date
JP2002275007A (en) 2002-09-25
US7060726B2 (en) 2006-06-13
US20040180951A1 (en) 2004-09-16
US7098244B2 (en) 2006-08-29
JP4424871B2 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
KR101997893B1 (en) Method of increase the bioactive effectiveness of sprout ginseng
JPWO2005072684A1 (en) Maca extract manufacturing method
US20090269424A1 (en) Peripheral blood flow-improving composition
KR101222778B1 (en) Antibacterial composition
JP4235254B2 (en) Methioninase inhibitor
JPH111429A (en) Anti-helicobacter pylori and food and drink for anti-gastritis, and gastric and duodenal ulcer, containing the same
US7098244B2 (en) Antibacterial agent
JPH1143442A (en) Legionella bacteria resistant composition
US20080020067A1 (en) Skin Moisturizer
JP5716385B2 (en) 3,5-dihydroxy-2-mentenylstilbene, plant extract containing the same, method for collecting the same and application thereof
EP1554938B1 (en) Flavor deterioration inhibitor and inhibitor for the generation of citral deterioration smell
JP3481269B2 (en) Antibacterial composition and antibacterial method
US20110135787A1 (en) Deodorizing composition using peroxidase under neutrality
EP1240832A2 (en) Antibacterial agent
KR20070029309A (en) A method for preparing extract of xanthoxylum piperitum and anti-cariogenic products containing extract of xanthoxylum piperitum
JP2004059525A (en) Antibacterial composition
JP7368858B2 (en) Biofilm formation inhibitor
JP4606099B2 (en) New compounds
JPH0834743A (en) Anticarious agent
JPH0358766A (en) Fragrant composition and product containing same composition
JP2006219471A (en) Arachidonic acid metabolism inhibitor
Das Sandalwood (Santalum album) oils
JPH06108087A (en) Method for stabilizing perfume

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAKASAGO INTERNATIONAL CORPORATION, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HIRAMOTO, TADAHIRO;TAKEUCHI, RYO;HANADA, MINORU;AND OTHERS;REEL/FRAME:012974/0275;SIGNING DATES FROM 20020505 TO 20020507

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553)

Year of fee payment: 12